Janux Therapeutics, Inc. Increase (Decrease) in Notes Payable, Current
Janux Therapeutics, Inc. (JANX) reported Increase (Decrease) in Notes Payable, Current of $0 for the 3-month period ending 2020-09-30, per its 10-Q filed 2021-11-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInNotesPayableCurrent · last filed 2021-11-09
- Janux Therapeutics, Inc. increase (decrease) in notes payable, current for the quarter ending 2020-09-30 was $0.00.
- Janux Therapeutics, Inc. increase (decrease) in notes payable, current for the quarter ending 2020-06-30 was $1.20M.
| Period end | Increase (Decrease) in Notes Payable, Current 3 month | Increase (Decrease) in Notes Payable, Current 6 month | Increase (Decrease) in Notes Payable, Current 9 month |
|---|---|---|---|
| 2020-09-30 | $0.00 10-Q · filed 2021-11-09 | $1.20M derived: sum of 2 quarters · filed 2021-11-09 | $1.70M 10-Q · filed 2021-11-09 |
| 2020-06-30 | $1.20M 10-Q · filed 2021-08-10 | $1.70M 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |